Nicholas Investment Partners LP bought a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 49,929 shares of the medical research company’s stock, valued at approximately $5,904,000.

Other hedge funds have also recently made changes to their positions in the company. South Texas Money Management Ltd. boosted its stake in Edwards Lifesciences Corporation by 157.9% during the first quarter. South Texas Money Management Ltd. now owns 344,816 shares of the medical research company’s stock valued at $32,437,000 after buying an additional 211,119 shares in the last quarter. Financial Counselors Inc. boosted its stake in Edwards Lifesciences Corporation by 2.1% during the first quarter. Financial Counselors Inc. now owns 13,637 shares of the medical research company’s stock valued at $1,283,000 after buying an additional 282 shares in the last quarter. Westpac Banking Corp boosted its stake in Edwards Lifesciences Corporation by 13.5% during the second quarter. Westpac Banking Corp now owns 14,214 shares of the medical research company’s stock valued at $1,681,000 after buying an additional 1,691 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Edwards Lifesciences Corporation by 41.9% during the second quarter. Principal Financial Group Inc. now owns 465,885 shares of the medical research company’s stock valued at $55,086,000 after buying an additional 137,643 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its stake in Edwards Lifesciences Corporation by 17.4% during the first quarter. Ameriprise Financial Inc. now owns 5,737,459 shares of the medical research company’s stock valued at $539,685,000 after buying an additional 850,168 shares in the last quarter. 82.08% of the stock is owned by institutional investors and hedge funds.

Several research analysts recently weighed in on EW shares. BidaskClub raised Edwards Lifesciences Corporation from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 22nd. BMO Capital Markets reaffirmed a “buy” rating and set a $132.00 target price on shares of Edwards Lifesciences Corporation in a research note on Friday, September 1st. Zacks Investment Research raised Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 target price for the company in a research note on Tuesday, July 18th. Cowen and Company reaffirmed an “outperform” rating and set a $135.00 target price (up previously from $130.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $115.00 target price on shares of Edwards Lifesciences Corporation in a research note on Friday, June 30th. Six research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $120.75.

TRADEMARK VIOLATION WARNING: This report was first published by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.dailypolitical.com/2017/09/18/nicholas-investment-partners-lp-buys-shares-of-49929-edwards-lifesciences-corporation-ew.html.

In related news, CEO Michael A. Mussallem sold 32,900 shares of the company’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $112.45, for a total transaction of $3,699,605.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,600 shares of the company’s stock in a transaction dated Thursday, June 29th. The stock was sold at an average price of $117.15, for a total value of $656,040.00. The disclosure for this sale can be found here. Insiders have sold 163,541 shares of company stock worth $18,712,719 in the last quarter. 2.13% of the stock is currently owned by corporate insiders.

Shares of Edwards Lifesciences Corporation (NYSE EW) traded down 0.94% on Monday, reaching $112.43. The company’s stock had a trading volume of 229,641 shares. Edwards Lifesciences Corporation has a 1-year low of $81.12 and a 1-year high of $121.75. The company’s 50 day moving average is $113.99 and its 200-day moving average is $108.88. The stock has a market cap of $23.74 billion, a PE ratio of 34.10 and a beta of 0.64.

Edwards Lifesciences Corporation (NYSE:EW) last released its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The business had revenue of $842.00 million for the quarter, compared to analyst estimates of $839.16 million. During the same quarter in the prior year, the company posted $0.76 earnings per share. Edwards Lifesciences Corporation’s revenue was up 10.9% on a year-over-year basis. On average, equities analysts predict that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current fiscal year.

Edwards Lifesciences Corporation Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.